ArticleCancer discovery2016
Developing EZH2-Targeted Therapy for Lung Cancer.
Article in Cancer discovery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.BioMed research international · 2020Pooled it
- EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2.Oncogene · 2026Article
- Therapeutic targeting of chromatin alterations in leukemia and solid tumors.International journal of cancer · 2026Review
- AKR1B1 is Required for Maintaining Acute Leukemia Cell Survival by Epigenetic Silencing of Tumor Suppressor Genes.Biochemical genetics · 2025Article
- Comorbidity of hypertension and lung cancer: interplay of genetics and environment.Discover oncology · 2025Review
- The golden key to open mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor: focusing immunotherapy, tumor microenvironment and epigenetic regulation.Cancer gene therapy · 2024Review
- Tazemetostat decreases β-catenin and CD13 protein expression in HEPG-2 and Hepatitis B virus-transfected HEPG-2 with decreased cell viability.Clinical epigenetics · 2023Article
- Inhibition of EZH2 exerts antitumorigenic effects in renal cell carcinoma via LATS1.FEBS open bio · 2023Article
- PAR-Induced Harnessing of EZH2 to β-Catenin: Implications for Colorectal Cancer.International journal of molecular sciences · 2022Article
- CBX2 and EZH2 cooperatively promote the growth and metastasis of lung adenocarcinoma.Molecular therapy. Nucleic acids · 2022Article
- Tumor-suppressive function of EZH2 is through inhibiting glutaminase.Cell death & disease · 2021Article
- Long non-coding RNAs in lung cancer: implications for lineage plasticity-mediated TKI resistance.Cellular and molecular life sciences : CMLS · 2021Review
- HMGA1 induces EZH2 overexpression in human B-cell lymphomas.American journal of cancer research · 2021Article
- Review
- EZH2 enhances expression of CCL5 to promote recruitment of macrophages and invasion in lung cancer.Biotechnology and applied biochemistry · 2020Article
- Symphony of epigenetic and metabolic regulation-interaction between the histone methyltransferase EZH2 and metabolism of tumor.Clinical epigenetics · 2020Review
- [Role of EZH2 Inhibitor Combined with Gefitinib in EGFR-TKIs Resistant Lung Cancer Cells].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Article
- Identification of SUV39H2 as a potential oncogene in lung adenocarcinoma.Clinical epigenetics · 2018Article
- Lung Cancer Therapy Targeting Histone Methylation: Opportunities and Challenges.Computational and structural biotechnology journal · 2018Review
- Small-cell lung cancer: what we know, what we need to know and the path forward.Nature reviews. Cancer · 2017Review
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
Abstract
Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinoma models expressing high levels of EZH2. Cancer Discov; 6(9); 949-52. ©2016 AACRSee related article by Zhang and colleagues, p. 1006.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.